Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report
Open Access
- 28 January 2020
- journal article
- case report
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-4
Abstract
Background: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). Case presentation: A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%. Conclusions: Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2017
- Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertensionJournal of Pharmaceutical and Biomedical Analysis, 2017
- Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal DiseaseAntimicrobial Agents and Chemotherapy, 2016
- Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patientsWorld Journal of Nephrology, 2015
- The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 GenotypeBasic & Clinical Pharmacology & Toxicology, 2014
- HIV and the aging kidneyCurrent Opinion in HIV and AIDS, 2014
- Pulmonary hypertension in patients with chronic and end-stage kidney diseaseKidney International, 2013
- Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1European Journal of Clinical Pharmacology, 2013
- Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participantsAntiviral Therapy, 2010
- Factors influencing the removal rate of drugs by hemodialysisNihon Toseki Igakkai Zasshi, 2004